Ingenza embarks on GSK collaboration

July 22, 2015 - PRLog -- Ingenza Ltd, a world leader in the application of industrial biotechnology and synthetic biology, is pleased to announce that it is collaborating with global healthcare company GlaxoSmithKline (GSK) on an innovative research project.

A vital part of any collaboration is the selection of a trusted partner. Andrew Collis, Synthetic Biochemistry Lead in GSK Global Manufacturing and Supply, explained why the company chose to work with Ingenza: “In any external collaboration, it is essential to partner with a company that can quickly and efficiently deliver GSK’s proof of concept. It is important to choose a partner that will interact well with our own scientists, with an established track record in the field. We look for a company with the right technical capabilities, that can understand our objectives and the science involved, and is able to engage in productive dialogue with our scientific staff to drive the project forward in a focused manner. Ingenza is a well-established company, which we believe to have the right skill set, attitude and facilities to progress our project and meet our targets and deadlines.”

Ian Fotheringham, Managing Director of Ingenza, commented: “Ingenza is delighted to be collaborating with GSK, using its extensive experience in the field to help deliver the project quickly and efficiently. We look forward to establishing an excellent relationship with GSK as the project progresses, working together to advance healthcare developments.”

About Ingenza

Ingenza is a worldwide leaders in the application of industrial biotechnology and synthetic biology, providing efficient scalable bioprocesses to manufacture chemicals, biologics, pharmaceuticals and biofuels, from sustainable sources. Its scientific and commercial activities are led by a management team with over 25 years’ experience in applied bioscience and the development and commercialisation of bio-based products. In addition to engaging in strategic partnerships to tailor its bioprocess services for clients, the company also licenses its proprietary bioprocess technologies.